| Product Code: ETC9978109 | Publication Date: Sep 2024 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Dhaval Chaurasia | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 United States (US) Thyroid Cancer Drug Market Overview |
3.1 United States (US) Country Macro Economic Indicators |
3.2 United States (US) Thyroid Cancer Drug Market Revenues & Volume, 2021 & 2031F |
3.3 United States (US) Thyroid Cancer Drug Market - Industry Life Cycle |
3.4 United States (US) Thyroid Cancer Drug Market - Porter's Five Forces |
3.5 United States (US) Thyroid Cancer Drug Market Revenues & Volume Share, By Type, 2021 & 2031F |
3.6 United States (US) Thyroid Cancer Drug Market Revenues & Volume Share, By Drug Type, 2021 & 2031F |
3.7 United States (US) Thyroid Cancer Drug Market Revenues & Volume Share, By Route of Administration, 2021 & 2031F |
3.8 United States (US) Thyroid Cancer Drug Market Revenues & Volume Share, By End User, 2021 & 2031F |
4 United States (US) Thyroid Cancer Drug Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of thyroid cancer in the United States |
4.2.2 Advancements in research and development of thyroid cancer drugs |
4.2.3 Growing awareness and early diagnosis of thyroid cancer |
4.3 Market Restraints |
4.3.1 Stringent regulatory requirements for drug approval |
4.3.2 High cost of treatment and medications |
4.3.3 Competition from alternative treatment options |
5 United States (US) Thyroid Cancer Drug Market Trends |
6 United States (US) Thyroid Cancer Drug Market, By Types |
6.1 United States (US) Thyroid Cancer Drug Market, By Type |
6.1.1 Overview and Analysis |
6.1.2 United States (US) Thyroid Cancer Drug Market Revenues & Volume, By Type, 2021- 2031F |
6.1.3 United States (US) Thyroid Cancer Drug Market Revenues & Volume, By Papillary Thyroid Cancer, 2021- 2031F |
6.1.4 United States (US) Thyroid Cancer Drug Market Revenues & Volume, By Follicular Thyroid Cancer, 2021- 2031F |
6.1.5 United States (US) Thyroid Cancer Drug Market Revenues & Volume, By Hurthle Cell Cancer, 2021- 2031F |
6.1.6 United States (US) Thyroid Cancer Drug Market Revenues & Volume, By Medullary Thyroid Cancer (MTC), 2021- 2031F |
6.1.7 United States (US) Thyroid Cancer Drug Market Revenues & Volume, By Anaplastic Thyroid Cancer, 2021- 2031F |
6.2 United States (US) Thyroid Cancer Drug Market, By Drug Type |
6.2.1 Overview and Analysis |
6.2.2 United States (US) Thyroid Cancer Drug Market Revenues & Volume, By Thyroid Desiccated, 2021- 2031F |
6.2.3 United States (US) Thyroid Cancer Drug Market Revenues & Volume, By Sorafenib, 2021- 2031F |
6.2.4 United States (US) Thyroid Cancer Drug Market Revenues & Volume, By Thyrotropin Alfa, 2021- 2031F |
6.2.5 United States (US) Thyroid Cancer Drug Market Revenues & Volume, By Vandetanib, 2021- 2031F |
6.2.6 United States (US) Thyroid Cancer Drug Market Revenues & Volume, By Doxorubicin, 2021- 2031F |
6.2.7 United States (US) Thyroid Cancer Drug Market Revenues & Volume, By Cabozantinib, 2021- 2031F |
6.2.8 United States (US) Thyroid Cancer Drug Market Revenues & Volume, By Sodium Iodide I-131, 2021- 2031F |
6.2.9 United States (US) Thyroid Cancer Drug Market Revenues & Volume, By Sodium Iodide I-131, 2021- 2031F |
6.2.10 United States (US) Thyroid Cancer Drug Market Revenues & Volume, By Dabrafenib, 2021- 2031F |
6.3 United States (US) Thyroid Cancer Drug Market, By Route of Administration |
6.3.1 Overview and Analysis |
6.3.2 United States (US) Thyroid Cancer Drug Market Revenues & Volume, By Oral, 2021- 2031F |
6.3.3 United States (US) Thyroid Cancer Drug Market Revenues & Volume, By Injectable, 2021- 2031F |
6.3.4 United States (US) Thyroid Cancer Drug Market Revenues & Volume, By Others, 2021- 2031F |
6.4 United States (US) Thyroid Cancer Drug Market, By End User |
6.4.1 Overview and Analysis |
6.4.2 United States (US) Thyroid Cancer Drug Market Revenues & Volume, By Hospitals, 2021- 2031F |
6.4.3 United States (US) Thyroid Cancer Drug Market Revenues & Volume, By Homecare, 2021- 2031F |
6.4.4 United States (US) Thyroid Cancer Drug Market Revenues & Volume, By Specialty Clinics, 2021- 2031F |
6.4.5 United States (US) Thyroid Cancer Drug Market Revenues & Volume, By Others, 2021- 2031F |
7 United States (US) Thyroid Cancer Drug Market Import-Export Trade Statistics |
7.1 United States (US) Thyroid Cancer Drug Market Export to Major Countries |
7.2 United States (US) Thyroid Cancer Drug Market Imports from Major Countries |
8 United States (US) Thyroid Cancer Drug Market Key Performance Indicators |
8.1 Average survival rate of patients diagnosed with thyroid cancer |
8.2 Adoption rate of new thyroid cancer drugs in clinical practice |
8.3 Number of research studies and clinical trials related to thyroid cancer treatment |
8.4 Patient satisfaction with the efficacy and tolerability of thyroid cancer drugs |
8.5 Rate of recurrence of thyroid cancer among patients undergoing drug therapy |
9 United States (US) Thyroid Cancer Drug Market - Opportunity Assessment |
9.1 United States (US) Thyroid Cancer Drug Market Opportunity Assessment, By Type, 2021 & 2031F |
9.2 United States (US) Thyroid Cancer Drug Market Opportunity Assessment, By Drug Type, 2021 & 2031F |
9.3 United States (US) Thyroid Cancer Drug Market Opportunity Assessment, By Route of Administration, 2021 & 2031F |
9.4 United States (US) Thyroid Cancer Drug Market Opportunity Assessment, By End User, 2021 & 2031F |
10 United States (US) Thyroid Cancer Drug Market - Competitive Landscape |
10.1 United States (US) Thyroid Cancer Drug Market Revenue Share, By Companies, 2024 |
10.2 United States (US) Thyroid Cancer Drug Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |